# 2016

# FY 2015 EARNINGS Roadshow UK- Gilbert Dupont May 9, 2016



# SAFE HARBOR STATEMENT

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward-looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regarding future events, and are based on currently available information. Consequently the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of. For additional information concerning these and other important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the 'Autorité des Marchés Financiers'.





# A Strategy Based on Innovation

### Successful strategic refocusing

- New operational organization
- Financial flexibility

### Continue investment

• SaaS, Digital, Big Data

### Numerous opportunities

- Government reforms
- New technologies
- Increasing complexity of medical knowledge
- New ways of delivering healthcare



Business Group Review






# **Our Clients, Our business**

### Healthcare

### All Industries



\*connected companies

# Roadmap for Profitable and Sustainable Growth

### 2015

- **Disposal** of the *CRM* and Strategic Data division
- Acquisition of Activus
  and US asset of
  Nightingale
- Beginning of Cegedim
  transformation

# cegedim

### 2016 - 2017


### Group Transformation

- Management evolution
- Organization change
- Significant investment

### 2018

- Full benefit of Group transformation
- Well positioned for coming years







# **Cegedim Investments**



Product Update

- Upgrades to reflects market changes
- Introduce new offer



2015 - 2016: Positioning Cegedim for Growth

SaaS / Cloud

- All new solutions will be Cloud based
- Reduce cost of development, maintenance and production
- Drives more recurring revenue
- Added value proposal



**BPO** 

- Process efficiency
- Reduce costs
- Flexibility in scaling
- Trends toward more outsourcing

# **Cegedim Insurance Solutions**

### Regulatory trends

• Dramatic changes with ACS, ANI, Sustainable contracts

- Technological trends
- Transition to SaaS

### Increase in addressable market

• Activus acquisition: access to new geographical market

### Third-party payment

- Generalization
- Process automation
- Monitoring rights online
- e-billing
- e-payment



# RNP

Enable brands to deliver best in class ROI through in store in and out visibility

### Activity

- Up to 20,000 pharmacies
- 4,500 sqm production and logistic center
- Internal studio
- Innovative online reporting tools

### New Contrat

aedim

- Carrefour
- 120 screens

### Great technology

- Size of the screen
- Pitch
- Brightness

### Prime locations

- Turnover
- Traffic
- Choice of window

### Great audience

# 560.000

Audience of a national campaign deployed RNP in 5,000 pharmacies \*

## 585.000

### Median audience of a DTT channel \*\*

\*Illustration for a RNP campaign lasting three weeks deployed in 5000 Pharmacies

\*\* Data based on 2015 Médiamétrie calculation

# **Cegedim SRH**

### A growing market


- HRIS market recorded a 4% increase in 2015
- Revenue growth by
  2.5 times between
  2009 and 2015



• • •

### Multiple drivers

- Regulatory drivers
- SaaS, Digital
- Low level of outsourcing





# **Cegedim e-business**

Cegedim's dematerialization operator






- Regulatory trend
  Digit
- Digitalization trend



# **Cegedim e-business**

### # of new customers signed per year



**cegedim** 

# **Cegedim Healthcare Professionals**

### Doctors

- Transition to SaaS
- Successful RCM
  model in US
- Adoption of IDC 10
- Docavenue
- Success in Drug database

### Pharmacists

- Difficult market
- New SaaS offering for the French market in H1-16

### Paramedics

- Success in
  - Rehabilitation tools
  - Solution for nurses

### **Drivers**

- Medicalization of software
- Increasing demand for Practice management software
- Connected devises
- Drug prescription and delivery software
- Telemedicine
- Coordination among HCPs'



# **Two Growth Factors**



- We have strong assets to build on
- Significant market
  opportunities
- Diversified revenue base and opportunities in new markets

External Growth

• Small bolt-on acquisition



2015 Financial Situation





# FY 2015 P&L Overview

In € million	2015*	2014*	Δ %
Revenue	426.2	412.2	+3.4%
EBITDA	78.5	78.0	+0.7%
EBIT before special items	48.1	51.6	(6.9)%
Net Earnings	47.0	(199.7)	n.m.
Net Earnings per share	4.8	(14.3)	n.m.

\* Restated figures for the Cegelease and Cegedim Kadrige impact

Impact of the Cegelease's restatement



# Cegelease activity has evolved:

In 2001	In 2015
Exclusive reseller of Group's products	Broker of financial leases
Cegedim: unique supplier	Many different suppliers
Payment solution for Pharmacist	Financing solutions for all healthcare professionals and others professionals
All contracts are self-financed	Majority of contract are resold to banks
Cegelease bears all the risk	The majority of risk is transferred to banks




# FY 2015 Revenue Restatement by Division

	Reported Jan.2016	Cegedim Kadrige Restatement	Cegelease Restatement
Health Insurance H.R. & e-services	236.6	234.7	234.7
Healthcare Professionals	152.1	152.1	187.2 (1)
Cegelease	117.0	117.0	
Activities not allocated	4.2	4.2	4.2
Cegedim	509.9	508.1	426.2



# Cegelase's Restatement Impact

This leads to a restatement of FY 2014 accounts and FY 2015 revenue in accordance with IAS 17. Impact on Revenue, EBITDA but not on EBIT



\* Not audited







Revenue €426.2m +3.4% reported +0.2% L-f-L

EBITDA €78.5m +0.7%

EPS €4.8



Group offering shifting to the cloud

Group Cloud and BPO offerings a success

Cegelease restatement

New 5 years RCF facility of €200m



2020 Bond will be called in Q2-16

The peak of transition is expected in 2016

2016 revenues and EBITDA are expected stable relative to 2015



# Revenue Growth

Division	FY 2014	L-f-L	Structure	Currency	Reported	FY 2015
Health Insurance H.R. & e-services	221.2	+4.4%	+1.7%	+0.0%	+6.1%	234.7
Healthcare Professionals	187.1	(4.8)%	+0.0%	+4.9%	+0.1%	187.2
Activities not allocated	3.9	+7.8%			+7.8%	4.2
Cegedim	412.2	+0.2%	+0.9%	+2.2%	+3.4%	426.2



# Well Diversified Revenue Sources



- Strong visibility across direct revenues streams
- Long-term contracts
- High retention rates in all business divisions



# FY-2015 P&L

In € million	FY 2015	FY 2014	% Change
Revenue	426.2	412.2	+3.4%
EBITDA	78.5	78.0	+0.7%
<i>margin</i> D&A	<i>18.4%</i> (30.4)	<i>18.9%</i> (26.3)	(49)bps +15.5%
EBIT before special items	48.1	51.6	(6.9)%
margin	11.3%	12.5%	(124)bps
Special items	(6.7)	(11.0)	+39.6%
EBIT	41.4	40.6	+2.0%
margin	9.7%	9.8%	(13)bps
Cost of net financial debt	(40.8)	(47.7)	(14.5)%
Total taxes	17.6	(1.6)	n.m.
Earnings from continuing activities	19.5	(7.5)	n.m.
Earnings from discontinued activities	47.5	(192.2)	n.m.
Net Earnings	67.0	(199.7)	n.m.
Earnings per share	4.8	(14.3)	n.m.

cegedim

# Robust Margin by Division

		alth Insi R. & e-se		Healthcare Professionals		Activities not allocated			
	FY 15	FY 14	$\Delta\%$	FY 15	FY 14	$\Delta\%$	FY 15	FY 14	Δ%
Revenue	234.7	221.2	+6.1%	187.2	187.1	+0.1%	4.2	3.9	+7.8%
EBITDA	46.5	43.7	+6.4%	30.0	39.1	(23.1)%	2.0	(4.8)	n.m.
D&A	(16.0)	(15.0)	+6.7%	(11.3)	(10.0)	+13.0%	(3.1)	(1.3)	n.s.
EBIT before special items	30.5	28.7	+6.2%	18.7	29.1	(35.5)%	(1.1)	(6.1)	n.s.
		<b>9.8%</b> DA mai			<b>6.0%</b> DA mai			<b>n.m</b> . DA mai	




# Consolidated Balance Sheet (in €m)

Assets	2015	2014
Goodwill	188.5	175.4
Other non-current assets	223.7	185.4
Cash & cash equivalents	231.3	44.0
Other current assets	220.0	183.6
Assets held for sale	0.8	584.9
Shareholders Equity & Liabiliti	es	
Shareholders Equity & Liabiliti	i <b>es</b> 228.1	216.7
		216.7 48.4
Shareholders Equity <sup>(1)</sup>	228.1	
Shareholders Equity <sup>(1)</sup> Other non-current liabilities	228.1 44.3	48.4



Including minority interest
 Long-term and short-term deb

# Solid Capital Structure



egedim

This includes 0.3% of the shares of Cegedim S.A held by Cegedim S.A. as of March 31, 2016



# Managing the debt profile

New RCF facility of €200m with a 5 years maturity. Signed on January 2016.

Shareholder loan: maturity extended to Jan. 2021

6.75% bond 2020\*: Full redemption on April 1<sup>st</sup>, 2016.

\* Subject to various standard conditions



# Significant Debt Reduction



2) Paid for partial redemption of the 6,75% bond maturing in 2020



# Group transformation continue Robust investment in R&D maintained for 2016 Transition to SaaS and BPO deployment Cegedim expects<sup>(1)</sup> to achieve stability with respect to both revenues and EBIDTA in 2016 despite the transition peak

(1) These projections are publicly disclosed on March 23, 2016. the fact that Cegedim include these projections in this presentation should not be taken to mean that these projections continue to be our projections as of any subsequent date. Please refer to point 3,7 "Outlook" in our 2015 Registration Document



### We welcome your questions and comments

Jan Eryk Umiastowski Chief Investment Officer – Head of Investor Relations

janeryk.umiastowski@cegedim.com Tel: 00 33 1 49 09 33 36 – Mob: 00 33 6 73 25 96 34

